Incorporating the Latest Therapeutic Advances and Shared Decision Making Into Clinical Practice
Audiocast Audiocast

Incorporating the Latest Therapeutic Advances and Shared Decision Making Into Clinical Practice


This activity was developed by Med-IQ in collaboration with the Association of Community Cancer Centers.

Med-IQ      ACCC
 

Released:
12/17/18
Expires:
12/16/19
PDF:

Maximum Credits:

0.5
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Audiocast Audiocast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
12/17/18

Expires:
12/16/19

PDF:

Maximum Credits:
0.5
Audiocast Audiocast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
12/17/18
Expires:
12/16/19
PDF:


Maximum Credits:
0.5


Overview: This 30-minute audiocast discusses the treatment of patients with advanced classical Hodgkin lymphoma (cHL), with a focus on novel therapeutic strategies both in first-line and refractory/relapsed settings. In addition, brief clinical case vignettes are included to illustrate how disease-, treatment-, and patient-related factors affect management decisions.

CME Information:

Faculty
Anas Younes, MD
Chief, Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
 
Stephen D. Smith, MD
Associate Professor, University of Washington
Clinical Director, SCCA Lymphoma
Associate Member, Fred Hutchinson Cancer Research Center
Seattle, WA
 
Activity Planners
Christie Avraamides, PhD
Clinical Content Manager
Med-IQ
Baltimore, MD
 
Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI

Leigh Boehmer, PharmD, BCOP
Medical Director, Education
Association of Community Cancer Centers
Rockville, MD

Learning Objectives
Upon completion, participants should be able to:

  • Tailor treatment regimens for patients with cHL to account for patient-, disease-, and treatment-related factors
  • Compare and contrast the efficacy and safety profiles of available treatments for cHL

Target Audience
This activity is intended for community-based hematologist/oncologists, hematology/oncology nurse practitioners, and hematology/oncology nurses.
 
Statement of Need
Classical Hodgkin lymphoma (cHL) is typically considered to be a curable disease; however, prognosis is poor for the approximately 20% of patients who do not respond to first- or second-line treatments. Fortunately, novel treatment regimens are now available for patients with cHL that may offer additional options for those with poor prognosis. Specifically, brentuximab vedotin was approved by the United States Food and Drug Administration (US FDA) in 2011 in the second-line treatment setting as consolidation therapy or in refractory or relapsed cHL. More recently, the FDA expanded brentuximab vedotin’s indication to include treatment-naïve stage III or IV cHL. In addition, 2 novel immune checkpoint inhibitors (pembrolizumab and nivolumab) were recently approved by the FDA for patients with relapsed or refractory cHL. The availability of these new therapeutic options in cHL places a substantial information burden on the hematologist/oncologists who are treating patients with this condition. This educational initiative will help these professionals update their knowledge of the benefits and risks of effective therapies while integrating newer therapy options into the current standard of care.
  
Collaboration Statement
This activity was developed by Med-IQ in collaboration with the Association of Community Cancer Centers.

Med-IQ      ACCC

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions to Receive Credit
To receive credit, read the introductory CME material, listen to the audiocast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: December 17, 2018
Expiration Date: December 16, 2019
Estimated Time to Complete This Activity: 30 minutes
 
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Stephen D. Smith, MD
Consulting fees/advisory boards: AstraZeneca, Merck & Co., Inc.
Contracted research: Acerta Pharma, Incyte Corporation, Merck & Co., Inc., Portola Pharmaceuticals, Inc., Seattle Genetics
 
Anas Younes, MD
Consulting fees/advisory boards: Bristol-Myers Squibb, Genentech, Incyte Corporation, Janssen Pharmaceuticals, Inc., Merck & Co., Inc.
Contracted research: Curis, Inc., F. Hoffman-La Roche Ltd., Johnson & Johnson, Novartis Pharmaceuticals Corporation

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information 
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.
 
System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Seattle Genetics.

Copyright
© 2018 Med-IQ, Inc.

 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.